Compare ASTL & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTL | FLGT |
|---|---|---|
| Founded | 1902 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.0M | 511.0M |
| IPO Year | 2021 | 2016 |
| Metric | ASTL | FLGT |
|---|---|---|
| Price | $4.96 | $19.28 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.64 | N/A |
| AVG Volume (30 Days) | ★ 924.9K | 246.0K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | N/A | $2.80 |
| Revenue Next Year | $68.36 | $15.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.16 | $13.46 |
| 52 Week High | $5.90 | $31.04 |
| Indicator | ASTL | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 63.42 | 39.99 |
| Support Level | $4.54 | $19.34 |
| Resistance Level | $5.25 | $20.02 |
| Average True Range (ATR) | 0.28 | 0.86 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 82.92 | 13.60 |
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from United States. The company generates the majority of its revenue from the sale of Steel sheets and strips.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.